What is Gilead Sciences?
Gilead Sciences, Inc. is a prominent biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines. The company focuses on addressing critical unmet medical needs across the United States, Europe, and globally. Its diverse portfolio includes treatments for HIV/AIDS, such as Biktarvy and Genvoya; COVID-19 therapies like Veklury; and treatments for viral hepatitis, including Epclusa and Harvoni. Furthermore, Gilead Sciences is actively involved in oncology with products like Yescarta and Tecartus, and also offers treatments for pulmonary arterial hypertension and serious fungal infections.
How much funding has Gilead Sciences raised?
Gilead Sciences has raised a total of $296.3M across 2 funding rounds:
Stock Offering
$86.3M
Other Financing Round
$210M
Stock Issuance/Offering (1992): $86.3M, investors not publicly disclosed
Other Financing Round (2024): $210M led by Abingworth
Key Investors in Gilead Sciences
Abingworth
Abingworth is a leading transatlantic life sciences investment firm that provides capital and expertise to transform cutting-edge science into novel medicines. Their therapeutic-focused investments span seed, early-stage, development stage, and clinical co-development.
What's next for Gilead Sciences?
The substantial enterprise-level funding and recent strategic investment indicate a strong trajectory for Gilead Sciences. This capital infusion is likely to accelerate the development of its robust pipeline, expand its market reach for existing therapies, and potentially fuel further research into novel therapeutic areas. The company's strategic collaborations with various leading biopharmaceutical entities suggest a forward-looking approach to innovation and market expansion, positioning Gilead Sciences for continued growth and impact in the global healthcare landscape.
See full Gilead Sciences company page
